Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 644

Results For "PAT"

6757 News Found

Max Ventilator forms partnership with US-based Amptron Medical
Drug Approval | September 07, 2021

Max Ventilator forms partnership with US-based Amptron Medical

Amptron’s R &D is based out of the US and this will enable Max to obtain US and other global certifications. Max will retain the right to market, sell and distribute the products in India.


Bajaj Healthcare gets a go-ahead for 2-Deoxy-D-Glucose to treat Covid-19
Drug Approval | September 06, 2021

Bajaj Healthcare gets a go-ahead for 2-Deoxy-D-Glucose to treat Covid-19

Marketed under the brand name DGJAJ, it helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence


DGCI approves Hetero’s Tocilizumab
Drug Approval | September 06, 2021

DGCI approves Hetero’s Tocilizumab

Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month


Accutest enables NMPA approval for Qilu’s Abiraterone
Drug Approval | September 06, 2021

Accutest enables NMPA approval for Qilu’s Abiraterone

The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India


NF Healthcare launch latest version of its oxygen generators
Healthcare | September 06, 2021

NF Healthcare launch latest version of its oxygen generators

The newest entrant from the company is the MOSS 1800F with an oxygen flow rate of 180 LPM or 10.8 Nm3/hour


HCG acquires oncology labs and divests stake in Strand Life Sciences
Healthcare | September 04, 2021

HCG acquires oncology labs and divests stake in Strand Life Sciences

The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business


Indian Railways to deploy HMIS across its network
Digitisation | September 04, 2021

Indian Railways to deploy HMIS across its network

Implementation of the system to provide faster, seamless and hassle-free healthcare solutions


Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent
Drug Approval | September 04, 2021

Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent

In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.


Novartis signs world’s first agreement with NHS, UK
News | September 03, 2021

Novartis signs world’s first agreement with NHS, UK

The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England


CII awards Excellence in Energy efficiency to Sai Life Sciences API unit
Sustainability | September 03, 2021

CII awards Excellence in Energy efficiency to Sai Life Sciences API unit

The Bidar API manufacturing facility of Sai Life Sciences has been on a path of significant expansion with its production capacity growing from 200KL in 2017 to 450KL